Protagonist Therapeutics price target raised to $45 from $42 at JMP Securities

JMP Securities analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics to $45 from $42 and keeps an Outperform rating on the shares. Management continues to execute well, completing enrollment of VERIFY on schedule with top-line data on track for 1Q24, the analyst tells investors in a research note. The firm is looking forward to the late-stage partnered readouts we think are relatively derisked and learning more about the internal candidates that will drive Protagonist’s future growth.